THOR hypermethylation has been found as an alternative telomerase-activating mechanism in cancer that can act independently or in conjunction with TERT promoter mutations, further supporting the utility of THOR hypermethylation as a prognostic biomarker (Lee et al., 2018). The gene discussed is TERT; the disease is cancer.